KR20140000627A - Medicinal herb composition for improvement, treatment and prevention of gastrointestinal motility disorders - Google Patents
Medicinal herb composition for improvement, treatment and prevention of gastrointestinal motility disorders Download PDFInfo
- Publication number
- KR20140000627A KR20140000627A KR1020130054029A KR20130054029A KR20140000627A KR 20140000627 A KR20140000627 A KR 20140000627A KR 1020130054029 A KR1020130054029 A KR 1020130054029A KR 20130054029 A KR20130054029 A KR 20130054029A KR 20140000627 A KR20140000627 A KR 20140000627A
- Authority
- KR
- South Korea
- Prior art keywords
- gastrointestinal
- extract
- fruit
- composition
- gastrointestinal motility
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 57
- 208000017228 Gastrointestinal motility disease Diseases 0.000 title claims abstract description 27
- 230000006872 improvement Effects 0.000 title description 6
- 238000011282 treatment Methods 0.000 title description 5
- 230000002265 prevention Effects 0.000 title description 4
- 239000000284 extract Substances 0.000 claims abstract description 83
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 67
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 17
- 208000003243 intestinal obstruction Diseases 0.000 claims abstract description 11
- 244000089698 Zanthoxylum simulans Species 0.000 claims abstract description 8
- 235000013399 edible fruits Nutrition 0.000 claims description 46
- 238000002360 preparation method Methods 0.000 claims description 18
- 230000002496 gastric effect Effects 0.000 claims description 17
- 239000002253 acid Substances 0.000 claims description 16
- 230000002980 postoperative effect Effects 0.000 claims description 16
- 208000012661 Dyskinesia Diseases 0.000 claims description 9
- 206010047700 Vomiting Diseases 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 8
- 230000008673 vomiting Effects 0.000 claims description 8
- 235000013305 food Nutrition 0.000 claims description 7
- 230000007160 gastrointestinal dysfunction Effects 0.000 claims description 7
- 238000002156 mixing Methods 0.000 claims description 7
- 206010054048 Postoperative ileus Diseases 0.000 claims description 6
- 201000006549 dyspepsia Diseases 0.000 claims description 6
- 206010010774 Constipation Diseases 0.000 claims description 5
- 208000021302 gastroesophageal reflux disease Diseases 0.000 claims description 5
- 239000012676 herbal extract Substances 0.000 claims description 5
- -1 C 4 alcohols Chemical class 0.000 claims description 4
- 235000002566 Capsicum Nutrition 0.000 claims description 4
- 206010033799 Paralysis Diseases 0.000 claims description 4
- 239000006002 Pepper Substances 0.000 claims description 4
- 235000016761 Piper aduncum Nutrition 0.000 claims description 4
- 235000017804 Piper guineense Nutrition 0.000 claims description 4
- 235000008184 Piper nigrum Nutrition 0.000 claims description 4
- 244000202052 Poncirus trifoliata Species 0.000 claims description 4
- 235000000404 Poncirus trifoliata Nutrition 0.000 claims description 4
- 239000004480 active ingredient Substances 0.000 claims description 4
- 206010009887 colitis Diseases 0.000 claims description 4
- 208000021090 palsy Diseases 0.000 claims description 4
- 244000183685 Citrus aurantium Species 0.000 claims description 3
- 235000007716 Citrus aurantium Nutrition 0.000 claims description 3
- 244000276331 Citrus maxima Species 0.000 claims description 3
- 235000001759 Citrus maxima Nutrition 0.000 claims description 3
- 235000000228 Citrus myrtifolia Nutrition 0.000 claims description 3
- 235000016646 Citrus taiwanica Nutrition 0.000 claims description 3
- 206010068871 Myotonic dystrophy Diseases 0.000 claims description 3
- 244000131415 Zanthoxylum piperitum Species 0.000 claims description 3
- 235000008853 Zanthoxylum piperitum Nutrition 0.000 claims description 3
- 241001079064 Zanthoxylum schinifolium Species 0.000 claims description 3
- 238000002512 chemotherapy Methods 0.000 claims description 3
- 206010012601 diabetes mellitus Diseases 0.000 claims description 3
- 235000015872 dietary supplement Nutrition 0.000 claims description 3
- 235000013376 functional food Nutrition 0.000 claims description 3
- 239000012046 mixed solvent Substances 0.000 claims description 3
- 244000294617 Zanthoxylum alatum Species 0.000 claims description 2
- 235000004417 Zanthoxylum alatum Nutrition 0.000 claims description 2
- 241000070618 Zanthoxylum coreanum Species 0.000 claims description 2
- 230000036541 health Effects 0.000 claims description 2
- 244000203593 Piper nigrum Species 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 25
- 238000000605 extraction Methods 0.000 abstract description 20
- 231100000419 toxicity Toxicity 0.000 abstract description 19
- 230000001988 toxicity Effects 0.000 abstract description 19
- 238000001356 surgical procedure Methods 0.000 abstract description 12
- 239000007864 aqueous solution Substances 0.000 abstract description 5
- 235000008216 herbs Nutrition 0.000 abstract description 5
- 229940116257 pepper extract Drugs 0.000 abstract description 4
- 235000009932 Zanthoxylum simulans Nutrition 0.000 abstract 5
- 241001523486 Poncirus Species 0.000 abstract 4
- 230000000246 remedial effect Effects 0.000 abstract 1
- 238000012360 testing method Methods 0.000 description 15
- 230000007661 gastrointestinal function Effects 0.000 description 13
- 241000411851 herbal medicine Species 0.000 description 13
- 229940079593 drug Drugs 0.000 description 12
- 239000003814 drug Substances 0.000 description 12
- 238000002474 experimental method Methods 0.000 description 10
- 230000005176 gastrointestinal motility Effects 0.000 description 10
- 241000700159 Rattus Species 0.000 description 9
- 239000002904 solvent Substances 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 6
- 239000013642 negative control Substances 0.000 description 6
- 102000005962 receptors Human genes 0.000 description 6
- 108020003175 receptors Proteins 0.000 description 6
- 230000002195 synergetic effect Effects 0.000 description 6
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 5
- 208000031969 Eye Hemorrhage Diseases 0.000 description 5
- 208000007101 Muscle Cramp Diseases 0.000 description 5
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 5
- 230000003187 abdominal effect Effects 0.000 description 5
- 231100000517 death Toxicity 0.000 description 5
- 230000034994 death Effects 0.000 description 5
- 208000001780 epistaxis Diseases 0.000 description 5
- 230000001771 impaired effect Effects 0.000 description 5
- 208000011309 nasal bleeding Diseases 0.000 description 5
- 238000011084 recovery Methods 0.000 description 5
- 210000002784 stomach Anatomy 0.000 description 5
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 4
- UAHWPYUMFXYFJY-UHFFFAOYSA-N beta-myrcene Chemical compound CC(C)=CCCC(=C)C=C UAHWPYUMFXYFJY-UHFFFAOYSA-N 0.000 description 4
- CRPUJAZIXJMDBK-UHFFFAOYSA-N camphene Chemical compound C1CC2C(=C)C(C)(C)C1C2 CRPUJAZIXJMDBK-UHFFFAOYSA-N 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 239000000469 ethanolic extract Substances 0.000 description 4
- 230000000968 intestinal effect Effects 0.000 description 4
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 description 4
- 229920001993 poloxamer 188 Polymers 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 241000282472 Canis lupus familiaris Species 0.000 description 3
- 206010012735 Diarrhoea Diseases 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 241000722363 Piper Species 0.000 description 3
- 238000009835 boiling Methods 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 229940068517 fruit extracts Drugs 0.000 description 3
- 235000015203 fruit juice Nutrition 0.000 description 3
- 235000000891 standard diet Nutrition 0.000 description 3
- 231100000820 toxicity test Toxicity 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 230000032258 transport Effects 0.000 description 3
- 239000000052 vinegar Substances 0.000 description 3
- 235000021419 vinegar Nutrition 0.000 description 3
- COXVTLYNGOIATD-HVMBLDELSA-N CC1=C(C=CC(=C1)C1=CC(C)=C(C=C1)\N=N\C1=C(O)C2=C(N)C(=CC(=C2C=C1)S(O)(=O)=O)S(O)(=O)=O)\N=N\C1=CC=C2C(=CC(=C(N)C2=C1O)S(O)(=O)=O)S(O)(=O)=O Chemical compound CC1=C(C=CC(=C1)C1=CC(C)=C(C=C1)\N=N\C1=C(O)C2=C(N)C(=CC(=C2C=C1)S(O)(=O)=O)S(O)(=O)=O)\N=N\C1=CC=C2C(=CC(=C(N)C2=C1O)S(O)(=O)=O)S(O)(=O)=O COXVTLYNGOIATD-HVMBLDELSA-N 0.000 description 2
- 102000004980 Dopamine D2 Receptors Human genes 0.000 description 2
- 108090001111 Dopamine D2 Receptors Proteins 0.000 description 2
- 102000057413 Motilin receptors Human genes 0.000 description 2
- 108700040483 Motilin receptors Proteins 0.000 description 2
- 102000014415 Muscarinic acetylcholine receptor Human genes 0.000 description 2
- 108050003473 Muscarinic acetylcholine receptor Proteins 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- PXRCIOIWVGAZEP-UHFFFAOYSA-N Primaeres Camphenhydrat Natural products C1CC2C(O)(C)C(C)(C)C1C2 PXRCIOIWVGAZEP-UHFFFAOYSA-N 0.000 description 2
- 102220530816 Transcription factor SOX-9_P90E_mutation Human genes 0.000 description 2
- 210000001015 abdomen Anatomy 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- XCPQUQHBVVXMRQ-UHFFFAOYSA-N alpha-Fenchene Natural products C1CC2C(=C)CC1C2(C)C XCPQUQHBVVXMRQ-UHFFFAOYSA-N 0.000 description 2
- VYBREYKSZAROCT-UHFFFAOYSA-N alpha-myrcene Natural products CC(=C)CCCC(=C)C=C VYBREYKSZAROCT-UHFFFAOYSA-N 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 229930006739 camphene Natural products 0.000 description 2
- ZYPYEBYNXWUCEA-UHFFFAOYSA-N camphenilone Natural products C1CC2C(=O)C(C)(C)C1C2 ZYPYEBYNXWUCEA-UHFFFAOYSA-N 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- NEHNMFOYXAPHSD-UHFFFAOYSA-N citronellal Chemical compound O=CCC(C)CCC=C(C)C NEHNMFOYXAPHSD-UHFFFAOYSA-N 0.000 description 2
- 230000006735 deficit Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 229960003699 evans blue Drugs 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 235000001510 limonene Nutrition 0.000 description 2
- 229940087305 limonene Drugs 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- ARGKVCXINMKCAZ-UHFFFAOYSA-N neohesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(CO)O3)OC3C(C(O)C(O)C(C)O3)O)=CC(O)=C2C(=O)C1 ARGKVCXINMKCAZ-UHFFFAOYSA-N 0.000 description 2
- 231100000957 no side effect Toxicity 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 210000000813 small intestine Anatomy 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 239000000341 volatile oil Substances 0.000 description 2
- 238000003809 water extraction Methods 0.000 description 2
- 239000001100 (2S)-5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)chroman-4-one Substances 0.000 description 1
- NLAWPKPYBMEWIR-SKYQDXIQSA-N (2S)-poncirin Chemical compound C1=CC(OC)=CC=C1[C@H]1OC2=CC(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O[C@H]3[C@@H]([C@H](O)[C@@H](O)[C@H](C)O3)O)=CC(O)=C2C(=O)C1 NLAWPKPYBMEWIR-SKYQDXIQSA-N 0.000 description 1
- WUOACPNHFRMFPN-SECBINFHSA-N (S)-(-)-alpha-terpineol Chemical compound CC1=CC[C@@H](C(C)(C)O)CC1 WUOACPNHFRMFPN-SECBINFHSA-N 0.000 description 1
- WEEGYLXZBRQIMU-UHFFFAOYSA-N 1,8-cineole Natural products C1CC2CCC1(C)OC2(C)C WEEGYLXZBRQIMU-UHFFFAOYSA-N 0.000 description 1
- 239000001606 7-[(2S,3R,4S,5S,6R)-4,5-dihydroxy-6-(hydroxymethyl)-3-[(2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-2-yl]oxy-5-hydroxy-2-(4-hydroxyphenyl)chroman-4-one Substances 0.000 description 1
- 108060003345 Adrenergic Receptor Proteins 0.000 description 1
- 102000017910 Adrenergic receptor Human genes 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 241001474374 Blennius Species 0.000 description 1
- 241000252233 Cyprinus carpio Species 0.000 description 1
- WEEGYLXZBRQIMU-WAAGHKOSSA-N Eucalyptol Chemical compound C1C[C@H]2CC[C@]1(C)OC2(C)C WEEGYLXZBRQIMU-WAAGHKOSSA-N 0.000 description 1
- PSMFFFUWSMZAPB-UHFFFAOYSA-N Eukalyptol Natural products C1CC2CCC1(C)COCC2(C)C PSMFFFUWSMZAPB-UHFFFAOYSA-N 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- QUQPHWDTPGMPEX-UHFFFAOYSA-N Hesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(COC4C(C(O)C(O)C(C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-UHFFFAOYSA-N 0.000 description 1
- 206010021333 Ileus paralytic Diseases 0.000 description 1
- 201000005081 Intestinal Pseudo-Obstruction Diseases 0.000 description 1
- 241000218922 Magnoliophyta Species 0.000 description 1
- 244000183278 Nephelium litchi Species 0.000 description 1
- 235000015742 Nephelium litchi Nutrition 0.000 description 1
- TWGHMXOYRUTQOL-UHFFFAOYSA-N O-Methylconfusameline Natural products COC1=C2C=COC2=NC2=CC(OC)=CC=C21 TWGHMXOYRUTQOL-UHFFFAOYSA-N 0.000 description 1
- 235000004347 Perilla Nutrition 0.000 description 1
- 244000124853 Perilla frutescens Species 0.000 description 1
- NLAWPKPYBMEWIR-VGQRFNKBSA-N Poncirin Natural products O([C@H]1[C@@H](O)[C@H](O)[C@H](CO)O[C@H]1Oc1cc(O)c2C(=O)C[C@@H](c3ccc(OC)cc3)Oc2c1)[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](C)O1 NLAWPKPYBMEWIR-VGQRFNKBSA-N 0.000 description 1
- 238000012356 Product development Methods 0.000 description 1
- SLSIBLKBHNKZTB-UHFFFAOYSA-N Skimmianine Chemical compound COC1=C2C=COC2=NC2=C(OC)C(OC)=CC=C21 SLSIBLKBHNKZTB-UHFFFAOYSA-N 0.000 description 1
- VBIRCRCPHNUJAS-UHFFFAOYSA-N Xanthoxylol Chemical compound C1=C(O)C(OC)=CC(C2C3C(C(OC3)C=3C=C4OCOC4=CC=3)CO2)=C1 VBIRCRCPHNUJAS-UHFFFAOYSA-N 0.000 description 1
- 241000190021 Zelkova Species 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 102000030484 alpha-2 Adrenergic Receptor Human genes 0.000 description 1
- 108020004101 alpha-2 Adrenergic Receptor Proteins 0.000 description 1
- OVKDFILSBMEKLT-UHFFFAOYSA-N alpha-Terpineol Natural products CC(=C)C1(O)CCC(C)=CC1 OVKDFILSBMEKLT-UHFFFAOYSA-N 0.000 description 1
- 229940088601 alpha-terpineol Drugs 0.000 description 1
- 230000001668 ameliorated effect Effects 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000000729 antidote Substances 0.000 description 1
- RPMNUQRUHXIGHK-PYXJVEIZSA-N apigenin 7-O-neohesperidoside Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=C2C(=O)C=C(C=3C=CC(O)=CC=3)OC2=C1 RPMNUQRUHXIGHK-PYXJVEIZSA-N 0.000 description 1
- 229930034861 apigenin-7-O-neohesperidoside Natural products 0.000 description 1
- QUQPHWDTPGMPEX-UTWYECKDSA-N aurantiamarin Natural products COc1ccc(cc1O)[C@H]1CC(=O)c2c(O)cc(O[C@@H]3O[C@H](CO[C@@H]4O[C@@H](C)[C@H](O)[C@@H](O)[C@H]4O)[C@@H](O)[C@H](O)[C@H]3O)cc2O1 QUQPHWDTPGMPEX-UTWYECKDSA-N 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000004534 cecum Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- RFFOTVCVTJUTAD-UHFFFAOYSA-N cineole Natural products C1CC2(C)CCC1(C(C)C)O2 RFFOTVCVTJUTAD-UHFFFAOYSA-N 0.000 description 1
- 229930003633 citronellal Natural products 0.000 description 1
- 235000000983 citronellal Nutrition 0.000 description 1
- APSNPMVGBGZYAJ-GLOOOPAXSA-N clematine Natural products COc1cc(ccc1O)[C@@H]2CC(=O)c3c(O)cc(O[C@@H]4O[C@H](CO[C@H]5O[C@@H](C)[C@H](O)[C@@H](O)[C@H]5O)[C@@H](O)[C@H](O)[C@H]4O)cc3O2 APSNPMVGBGZYAJ-GLOOOPAXSA-N 0.000 description 1
- 238000011284 combination treatment Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 208000010643 digestive system disease Diseases 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 235000011869 dried fruits Nutrition 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 229930182486 flavonoid glycoside Natural products 0.000 description 1
- 150000007955 flavonoid glycosides Chemical class 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 208000018685 gastrointestinal system disease Diseases 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000000321 herbal drug Substances 0.000 description 1
- 230000002363 herbicidal effect Effects 0.000 description 1
- VUYDGVRIQRPHFX-UHFFFAOYSA-N hesperidin Natural products COc1cc(ccc1O)C2CC(=O)c3c(O)cc(OC4OC(COC5OC(O)C(O)C(O)C5O)C(O)C(O)C4O)cc3O2 VUYDGVRIQRPHFX-UHFFFAOYSA-N 0.000 description 1
- QUQPHWDTPGMPEX-QJBIFVCTSA-N hesperidin Chemical compound C1=C(O)C(OC)=CC=C1[C@H]1OC2=CC(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO[C@H]4[C@@H]([C@H](O)[C@@H](O)[C@H](C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-QJBIFVCTSA-N 0.000 description 1
- 229940025878 hesperidin Drugs 0.000 description 1
- 208000008384 ileus Diseases 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000000749 insecticidal effect Effects 0.000 description 1
- 244000000053 intestinal parasite Species 0.000 description 1
- 208000002551 irritable bowel syndrome Diseases 0.000 description 1
- DOMJKIVDRZSIJN-UHFFFAOYSA-N kokusaginine Natural products COC12Cc3ncccc3CC1(OC)C=CO2 DOMJKIVDRZSIJN-UHFFFAOYSA-N 0.000 description 1
- 238000002350 laparotomy Methods 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 230000007659 motor function Effects 0.000 description 1
- DFPMSGMNTNDNHN-ZPHOTFPESA-N naringin Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](OC=2C=C3O[C@@H](CC(=O)C3=C(O)C=2)C=2C=CC(O)=CC=2)O[C@H](CO)[C@@H](O)[C@@H]1O DFPMSGMNTNDNHN-ZPHOTFPESA-N 0.000 description 1
- 229930019673 naringin Natural products 0.000 description 1
- 229940052490 naringin Drugs 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- ARGKVCXINMKCAZ-UZRWAPQLSA-N neohesperidin Chemical compound C1=C(O)C(OC)=CC=C1[C@H]1OC2=CC(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O[C@H]3[C@@H]([C@H](O)[C@@H](O)[C@H](C)O3)O)=CC(O)=C2C(=O)C1 ARGKVCXINMKCAZ-UZRWAPQLSA-N 0.000 description 1
- 231100000989 no adverse effect Toxicity 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 201000007620 paralytic ileus Diseases 0.000 description 1
- 230000008855 peristalsis Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 235000021110 pickles Nutrition 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- RPMNUQRUHXIGHK-SBDOOABHSA-N rhoifolin Natural products O([C@@H]1[C@@H](O)[C@H](O)[C@H](CO)O[C@H]1Oc1cc(O)c2C(=O)C=C(c3ccc(O)cc3)Oc2c1)[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](C)O1 RPMNUQRUHXIGHK-SBDOOABHSA-N 0.000 description 1
- 238000002432 robotic surgery Methods 0.000 description 1
- SACPYSHBQFRBLR-UHFFFAOYSA-N skimmianine Natural products COC1=C2C=COC2Nc3c(OC)c(OC)ccc13 SACPYSHBQFRBLR-UHFFFAOYSA-N 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 238000002137 ultrasound extraction Methods 0.000 description 1
- 238000011870 unpaired t-test Methods 0.000 description 1
- BURBOJZOZGMMQF-UHFFFAOYSA-N xanthoxylol Natural products C1=C(O)C(OC)=CC=C1C1C(COC2C=3C=C4OCOC4=CC=3)C2CO1 BURBOJZOZGMMQF-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/752—Citrus, e.g. lime, orange or lemon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/758—Zanthoxylum, e.g. pricklyash
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/32—Foods, ingredients or supplements having a functional effect on health having an effect on the health of the digestive tract
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Mycology (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Nutrition Science (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Physiology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
본 발명은 위장관 운동 장애 질환의 개선, 치료 및 예방을 위한 생약 조성물에 관한 것으로, 특히 생약의 추출 조건 및 조성비를 조절함으로써 독성을 경감시킨 조성물에 관한 것이다. The present invention relates to a herbal composition for improving, treating, and preventing diseases of the gastrointestinal motility disorder, and more particularly, to a composition in which toxicity is reduced by adjusting extraction conditions and composition ratios of the herbal medicine.
위장관 운동 장애 질환은 위식도 역류성 질환, 기능성 소화불량, 과민성 대장염, 위장관 마비, 구토, 당뇨병성 위장운동장애, 화학요법으로 인한 위장운동장애, 소화관 운동장애로 인한 장폐색, 수술 후 장폐색을 포함하는 수술 후 위장관 기능 장애, 근긴장성 이영양증으로 인한 위장관 운동 장애 및 변비 등과 같이 정상적인 위장관 운동이 장애, 저해, 손상되어 있는 병적 상태를 말한다.Gastrointestinal motility disorders include surgery including gastroesophageal reflux disease, functional dyspepsia, irritable colitis, gastrointestinal palsy, vomiting, diabetic gastrointestinal disorder, gastrointestinal motility due to chemotherapy, bowel obstruction due to gastrointestinal motility disorder, postoperative ileus It refers to a pathological condition in which normal gastrointestinal motility is impaired, inhibited or impaired, such as gastrointestinal dysfunction, gastrointestinal dyskinesia due to myotonic dystrophy and constipation.
위장관 운동 장애 질환은 선진국은 물론 우리나라에서도 상당히 유병율이 높은 질환으로, 위식도 역류성 질환, 기능성 소화불량, 과민성 대장질환, 위장관 마비, 구토, 수술후 장폐색 및 변비 등 다양한 양상으로 나타나며, 위장관의 조직 병리학적 및 생화학적인 병변이 아닌 위장관 연동운동에 관련된 기능적 증상이다.Gastrointestinal motility disorder is a disease with high prevalence in developed countries as well as in Korea. Gastroesophageal reflux disease, functional dyspepsia, irritable bowel disease, gastrointestinal palsy, vomiting, postoperative intestinal obstruction and constipation. And functional symptoms related to gastrointestinal peristalsis rather than biochemical lesions.
지실(枳實)은 광귤나무(Citrus aurantium L) 또는 탱자나무(Poncirus trifoliata Rafin 또는 Citrus trifoliata)의 익지 않은 열매이다. 지실은 폰시린(poncirin), 헤스페리딘(hesperidin), 로이폴린(rhoifolin), 나린진(naringin), 네오헤스페리딘(neohesperidin) 등의 플라보노이드 배당체, 스키미아닌 (skimmianine) 등의 알칼로이드 성분, 그리고 피넨(pinene), 미르센(myrcene), 리모넨(limonene), 캄펜(camphene) 등의 정유성분이 함유된 것으로 알려져 있으며, 항알러지 작용이 있다. 한국특허 제10-635658호에서는 지실의 단독 추출물 또는 진피와 혼합한 추출물을 수술 후 장폐색 치료에 사용한 예를 개시하고 있으나, 실제 치료를 위해 투여된 양이 500 ㎎/5 ㎖/㎏ 내지 1 g/5 ㎖/㎏의 대용량으로(실험예 6 및 7), 실제 임상에서 활용되기에는 어려운 측면이 있다.It is an unripe fruit of Citrus aurantium L or Poncirus trifoliata Rafin or Citrus trifoliata. Fruits are alkaloids such as poncirin, hesperidin, rhoifolin, narifin, naringin, and neohesperidin, flavonoid glycosides, and skimmianine, and pinene. It is known to contain essential oils such as myrcene (myrcene), limonene (limonene), camphene (camphene), and has an anti-allergic effect. Korean Patent No. 10-635658 discloses an example in which ileus extract or mixed with dermis is used for post-operative intestinal obstruction, but the amount administered for the actual treatment is 500 mg / 5 ml / kg to 1 g /. With a large capacity of 5 ml / kg (Experimental Examples 6 and 7), there are aspects that are difficult to be utilized in actual clinical.
산초(山椒)는 운향과(Rutaceae)에 속하는 산초나무(Zanthoxylum)속 낙엽 활엽성 교목인 초피나무(Zanthoxylum piperitum), 또는 그 동속식물인 화초나무(Zanthoxylum bungeanum), 산초나무(Zanthoxylum schinifolium)의 과피로서, 천초, 화초, 촉초, 남초, 대초 등으로 불리운다. 산초의 성분으로는 산아미드 계통의 산숄 Ⅰ-Ⅳ와 정유성분으로는 시트로넬랄, 1,8-시네올, 디펜탄, α-터피네올 등이 함유되어 있고, 리그난 화합물인 크산토시롤(xanthoxylol) 등이 분리 보고되어 있으며, 건위 작용, 항균 및 살충 작용이 알려져 있고 장내 기생충 구제약, 충어독의 해독약으로 사용되기도 한다.Sancho is a deciduous broad-leaved deciduous tree, Zanthoxylum piperitum, or its equivalent plant, Zanthoxylum bungeanum or Zanthoxylum schinifolium. As a vinegar, a flower, a candle, a seaweed, a weed, etc. are called. The acid component contains acid sulfol I-IV of acid amide, and essential oils include citronellal, 1,8-cineol, dipentane, α-terpineol, etc. (xanthoxylol) has been reported separately, and it is known for its sanitary, antibacterial and insecticidal effects. It is also used as an antidote for intestinal parasite control and carp poison.
지실과 산초는 예전부터 생약으로 사용되어 한방의약서 등에 기재되어 있지만 선행 기술 어디에도 지실과 산초를 조합하여 위장관 기능에 대하여 상승적인 개선 효과를 나타내었다는 내용이 교시되거나 개시된 바 없다.Although Jisil and Sancho have been used as herbal medicines in the past, they have been described in herbal medicines and the like. However, none of the prior arts has been taught or disclosed that synergistic improvement of gastrointestinal function has been shown by combining Jisil and Sancho.
본 발명자들은 위장관 기능 장애 치료 및 개선 효과를 나타내는 생약 조성물을 개발하기 위해 다양한 생약의 조합에 대하여 위장관 운동에 대한 효과를 확인하는 시험을 실시한 결과, 지실과 산초의 생약 추출물 조합이 위장관 운동에 뛰어난 효과를 나타내어 위장관 운동 장애 질환에 효과적으로 사용할 수 있음을 동물 실험을 통하여 확인하였다. 또한 생약 추출물의 추출 조건과 조합에 따른 독성의 변화를 동물 실험을 통하여 연구하였으며, 이들 결과를 조합하여 생약 조성물의 약효를 확보하면서 독성을 경감시킬 수 있도록 생약의 추출 조건 및 조성비를 조정하여 본 발명을 완성하게 되었다.The present inventors conducted a test for confirming the effect on the gastrointestinal motility for various combinations of herbal medicines to develop a herbal composition showing the effect of treating and improving gastrointestinal dysfunction. It was confirmed through animal experiments that can be effectively used for gastrointestinal motility disorders. In addition, changes in toxicity according to the extraction conditions and combinations of the herbal extracts were studied through animal experiments. By combining these results, the extraction conditions and composition ratios of the herbal medicines were adjusted to reduce the toxicity while securing the efficacy of the herbal compositions. To complete.
본 발명은 위장관 운동 장애 질환의 예방, 개선 또는 치료에 사용될 수 있는 탁월한 위장관 기능 개선 효과와 부작용이 없는 생약 조성물에서 약효를 확보하면서 생약의 추출 조건 및 구성 성분의 조성비를 조정하여 독성을 경감시킨 조성물을 제공하는 것을 목적으로 한다.The present invention is to reduce the toxicity by adjusting the extraction conditions and the composition of the components of the herbal medicine while securing the medicinal effect in the herbal composition without excellent gastrointestinal function improving effect and side effects that can be used for the prevention, improvement or treatment of gastrointestinal dyskinesia disorders The purpose is to provide.
상기 목적을 달성하기 위하여, 본 발명에서는 산초 및 지실 추출물을 유효성분으로 함유하는 위장관 운동 장애 질환의 개선, 치료 또는 예방용 생약 조성물에 있어서, 산초 추출물이 물 또는 30% 이하의 에탄올 수용액으로 추출한 것임을 특징으로 하는 조성물을 제공한다.In order to achieve the above object, in the present invention, in the herbal composition for improving, treating, or preventing gastrointestinal motility disorders, which contains an extract of Sancho and fruit juice as an active ingredient, the extract of Sancho is extracted with water or an aqueous ethanol solution of 30% or less. It provides a composition characterized by.
여기에서, 산초 및 지실 추출물의 혼합비는 1:8 이상인 것이 바람직하고, 1:8 내지 1:12 범위가 특히 바람직하다.Here, it is preferable that the mixing ratio of the sancho and fruit fruit extract is 1: 8 or more, and the range of 1: 8-1: 12 is especially preferable.
본 발명에서는 위장관 운동 촉진을 위해 부작용이 없으면서 효과가 좋은 생약 조성물의 개발을 위해 연구한 결과, 예전부터 사용되어 널리 알려져 있고 부작용이 거의 없는 생약인 산초 및 지실을 조합하여 사용할 경우 위장관 운동 촉진 효과가 매우 우수한 것을 밝혀냈다. 즉, 산초와 지실은 비록 소량이더라도 서로 조합 또는 병용하여 사용하게 되면, 각각 단독으로 사용하는 경우에 비하여 상승적인 위장관 기능 개선효과를 나타내었다. 또한, 산초 및 지실의 추출 용매와 조합 비율에 따른 독성의 변화를 동물 실험을 통하여 연구하였으며, 그 결과 생약 조성물의 약효를 확보하면서 독성을 경감시킬 수 있는 추출 용매 및 조성비를 발견하게 되었다.In the present invention, as a result of research for the development of a good herbal composition with no side effects to promote the gastrointestinal motility, the gastrointestinal motility promoting effect is used when used in combination with the herbaceous acid and liquor which is widely known and rarely used as a side effect It turned out to be very good. That is, even if a small amount of Sancho and Jisil used in combination or in combination with each other, each showed a synergistic gastrointestinal function improvement effect compared to the use alone. In addition, the change in toxicity according to the extraction ratio and the extraction solvent of the acid and fruit room was studied through animal experiments, and as a result, it was found that the extraction solvent and the composition ratio to reduce the toxicity while securing the efficacy of the herbal composition.
본 발명에 따른 산초 및 지실 추출물을 특정 조성비로 포함하는 조성물은 위장관 운동장애 질환의 개선, 치료 또는 예방용 경구제제, 그리고 기능성 위장관 운동장애 개선용 식품, 건강보조식품 또는 건강기능식품으로 사용될 수 있다.The composition comprising the extract of Sancho and fruit juice according to the present invention in a specific composition ratio can be used as an oral preparation for improving, treating or preventing gastrointestinal motility disorders, and as a food, health supplement or health functional food for improving functional gastrointestinal motility disorders. .
이하, 본 발명에 따른 산초 및 지실 추출물을 포함하는 조성물은 생약 조성물로 지칭한다.Hereinafter, the composition comprising the herb and fruit extract according to the present invention is referred to as a herbal composition.
한편, 본 발명의 생약 조성물을 구성하는 생약은 당업계에서 자명하게 동속에 해당하며 본 발명의 예방과 치료 목적과 동일 또는 유사한 용도로 사용할 수 있다고 여겨지는 동속 생약을 모두 포함한다.On the other hand, the herbal medicine constituting the herbal composition of the present invention obviously corresponds to the same in the art and includes all of the same herbal medicine that can be used for the same or similar purposes as the preventive and therapeutic purposes of the present invention.
구체적으로, 본 발명에서 산초(Zanthoxyli Fructus)는 초피나무 (Zanthoxylum piperitum), 그 동속식물인 화초나무(Zanthoxylum bungeanum), 산초나무(Zanthoxylum schinifolium), 개산초나무(Zanthoxylum armatum var subtrifoliatum) 또는 왕초피나무(Zanthoxylum coreanum)의 과피를 지칭한다.Specifically, the present invention (Zanthoxyli Fructus) is a vinegar (Zanthoxylum piperitum), its flowering plant (Zanthoxylum bungeanum), vinegar (Zanthoxylum schinifolium), zelkova (Zanthoxylum armatum var subtrifoliatum) or bark Zanthoxylum coreanum).
또한 본 발명에서 지실(Ponciri Fructus)은 국산 지실(Poncirus trifoliate), 중국산 지실(Citrus aurantium), 또는 그 동속식물인 왕귤나무(Citrus grandis)의 미숙과를 지칭한다.In the present invention, the fruit room (Ponciri Fructus) refers to the immature fruit of the domestic fruit room (Poncirus trifoliate), Chinese fruit room (Citrus aurantium), or the same plant as the citrus grandis (Citrus grandis).
본 발명의 생약 조성물에서 산초 및 지실 추출물은 각각의 생약을 함께 물 또는 물과 에탄올의 혼합용매로서 30% 이하의 에탄올 수용액으로 추출하여 수득될 수 있다. 산초와 지실을 별도로 추출하는 경우, 지실 추출 용매는 물 또는 30% 이하의 에탄올 수용액으로 한정되지 않고, 물, C1 내지 C4 알코올, 또는 이들의 혼합용매를 사용할 수 있다. C1 내지 C4 알코올로는 메탄올, 에탄올, 프로판올 및 부탄올을 예시할 수 있으며, 에탄올이 가장 바람직하다. 추출 용매는 생약 중량의 1 내지 50 배, 바람직하게는 약 3 내지 30 배 분량으로 사용할 수 있다.In the herbal composition of the present invention, the herbaceous and fruit extracts can be obtained by extracting each herbal with water or an aqueous ethanol solution of 30% or less as a mixed solvent of water and ethanol. In the case of extracting the acid and the fruit compartment separately, the fruit compartment extraction solvent is not limited to water or 30% or less ethanol aqueous solution, water, C 1 to C 4 alcohol, or a mixed solvent thereof may be used. Examples of the C 1 to C 4 alcohols include methanol, ethanol, propanol and butanol, with ethanol being most preferred. The extraction solvent may be used in an amount of 1 to 50 times, preferably about 3 to 30 times the weight of the herbal medicine.
상기 산초 및 지실의 추출물은 생약 추출 분야에서 당업자에 공지된 임의의 추출법에 의해 제조될 수 있으며, 예를 들어 5 내지 100 ℃, 바람직하게는 10 내지 80 ℃, 보다 바람직하게는 상온에서 약 1 내지 100 시간, 바람직하게는 8 내지 72 시간 동안 교반 추출, 열탕 추출, 냉침 추출, 환류 냉각 추출 또는 초음파 추출에 의해, 바람직하게는 냉침 추출로 제조할 수 있다. 수득한 추출액을 여과, 감압 농축 또는 건조하여 최종 추출물로서 얻을 수 있다.The extracts of Sancho and Jissil can be prepared by any extraction method known to those skilled in the art of herbal medicine extraction, for example, 5 to 100 ℃, preferably 10 to 80 ℃, more preferably about 1 to about room temperature It may be prepared by stirring extraction, boiling water extraction, cold extraction, reflux cooling extraction or ultrasonic extraction for 100 hours, preferably 8 to 72 hours, preferably by cold extraction. The obtained extract can be filtered, concentrated under reduced pressure or dried to obtain the final extract.
본 발명의 산초 및 지실 추출물을 포함하는 생약 조성물은 위장관 운동 장애 질환의 개선, 치료 또는 예방에 효과적이며, 특히 수술후 장폐색을 포함하는, 수술후 저하된 위장관 기능의 회복에 탁월한 효과를 나타낸다. The herbal compositions comprising the extracts of the herbaceous acid and fruiting fruit of the present invention are effective in improving, treating or preventing gastrointestinal motility disorders, and in particular, exhibit an excellent effect on the recovery of postoperative gastrointestinal function, including postoperative intestinal obstruction.
또한, 본 발명의 산초 및 지실 추출물의 조합으로 이루어지는 생약 조성물은 주성분인 산초 및 지실 추출물 각각을 단독으로 투여하는 경우에 비해 현저히 우수한 장내 이송율을 나타냄으로써, 이들 두 생약의 조합은 위장관 운동 장애 질환의 개선, 치료 및 예방에 있어서 상승 작용을 나타내는 것이 입증되었다.In addition, the herbal composition consisting of a combination of acid and fruit extract of the present invention exhibits a significantly superior intestinal transfer rate compared to the case of administering each of the main component of the extract and the main fruit extract, the combination of these two herbs is a gastrointestinal motility disorder disease Has been shown to exhibit synergistic effects in the improvement, treatment and prevention of
본 발명에서, 산초 및 지실 추출물은 5-HT4 수용체에 대한 효과, 도파민 D2 수용체에 대한 효과, 무스카린 수용체들에 대한 효과, 모틸린 수용체에 대한 효과, 아드레날린성 α2A 수용체에 대한 효과, 5-HT1A 수용체에 대한 효과를 나타내는 것이 확인되었다. 이와 같이, 본 발명에 따른 산초와 지실 추출물을 포함하는 생약 조성물은 5-HT4 등 위장관 운동에 영향을 미치는 다양한 수용체들의 작용을 조절하여, 복합적인 기전에 의해 기능성 소화불량 등 위장관 운동장애에 매우 뛰어난 치료효과를 나타낸다. 특히, 본 발명의 산초와 지실 추출물의 조합을 포함하는 생약 조성물은 이들의 상승 작용에 의해, 수술 후 위장관 기능 회복 실험에서 수술을 받지 않은 정상군을 상회하는 우수한 수술후 위장관 기능의 개선을 나타낸다. 따라서, 본 발명의 생약 조성물을 투여할 경우 수술로 인해 저하되었던 위장관 기능을 신속하게 회복시켜 빠른 퇴원이 가능하게 된다.In the present invention, Sancho and fruit extracts are effective on 5-HT 4 receptor, on dopamine D2 receptor, on muscarinic receptors, on motilin receptors, on adrenergic α2A receptors, 5- It was confirmed to exhibit an effect on the HT 1A receptor. As described above, the herbal composition comprising an extract of Sancho and Ji-sil according to the present invention regulates the action of various receptors affecting gastrointestinal motility, such as 5-HT 4, and is very effective in gastrointestinal motility disorders such as functional dyspepsia by a complex mechanism. Excellent therapeutic effect. In particular, the herbal compositions comprising a combination of Sancho and fruiting extracts of the present invention exhibit excellent synergistic post-operative gastrointestinal function improvement above their normal group in the postoperative gastrointestinal function recovery experiments by their synergistic action. Therefore, when the herbal composition of the present invention is administered, the gastrointestinal function, which has been degraded due to the surgery, is quickly restored, thereby enabling rapid discharge.
본원에서 정의되는 "위장관 운동장애 질환"은 정상적인 위장관 운동이 장애, 저해, 손상되어 있는 상태로 인한 질환을 지칭한다. 이러한 위장관 운동장애 질환으로는 위식도 역류성 질환, 기능성 소화불량, 과민성 대장염, 위장관 마비, 구토, 당뇨병성 위장운동장애, 화학요법으로 인한 위장운동장애, 소화관 운동장애로 인한 장폐색, 수술 후 장폐색을 포함하는 수술 후 위장관 기능 손상 및 저하, 근긴장성 이영양증으로 인한 위장관 운동장애 또는 변비 등을 들 수 있고, 바람직하게는, 위식도 역류성 질환, 기능성 소화불량, 과민성 대장염, 수술 후 위장관 기능 손상 및 저하, 그리고 변비를 예시할 수 있지만, 이들만으로 한정되지 않는다. 예컨대, 위장관 운동에 영향을 미치는 다양한 수용체, 즉 5-HT4 수용체, 도파민 D2 수용체, 무스카린 수용체, 모틸린 수용체, 아드레날린성 α2A 수용체 및 5-HT1A 수용체의 작용을 조절함으로써 개선 또는 치료될 수 있는 병적 상태는 본원에서 정의된 위장관 운동장애 질환에 포함된다.As used herein, “gastrointestinal motility disorder” refers to a disease caused by a condition in which normal gastrointestinal motility is impaired, inhibited, or impaired. These gastrointestinal motility disorders include gastroesophageal reflux disease, functional dyspepsia, irritable colitis, gastrointestinal palsy, vomiting, diabetic gastrointestinal dysfunction, gastrointestinal dyskinesia due to chemotherapy, intestinal obstruction due to gastrointestinal dyskinesia, and postoperative intestinal obstruction. Postoperative gastrointestinal function impairment and degradation, gastrointestinal dyskinesia or constipation due to myotonic dystrophy, and preferably, gastroesophageal reflux disease, functional dyspepsia, irritable colitis, postoperative gastrointestinal function impairment and degradation, and Although constipation can be illustrated, it is not limited only to these. For example, it can be ameliorated or treated by modulating the action of various receptors that affect gastrointestinal motility, namely 5-HT 4 receptor, dopamine D2 receptor, muscarinic receptor, motilin receptor, adrenergic α2A receptor and 5-HT 1A receptor. Pathological conditions that are included are included in the gastrointestinal motility disorders defined herein.
본원에서 정의되는 "수술 후 위장관 기능 장애"는 수술로 인하여 일시적으로 위장관 기능이 손상되거나 저하되어 있는 상태를 말하며, 수술 후 장폐색을 포함한다. 수술 후 장폐색은 임상적으로 개복수술 후 발생하는 위장관 운동 기능의 저해 상황을 의미하며 수술 후 위장관 기능의 빠른 회복은 퇴원 시기를 앞당기는 결정적인 요소가 된다. 일반적으로 개복 수술 후 2∼3일 이내에 위장관 운동 기능이 정상적으로 회복되는데, 종종 자연적으로 치유되지 않고 3일 이상 경과하는 마비성 장폐색으로 진행되기도 한다. 수술은 개복 수술뿐만 아니라 복강경이나 관절경 및 기타 로봇 수술을 포함하여 의미하며, 대장 소장 질환 수술뿐만 아니라 자궁 및 기타 기관의 수술도 포함한다.As defined herein, “postoperative gastrointestinal dysfunction” refers to a condition in which gastrointestinal function is temporarily impaired or degraded due to surgery, and includes postoperative ileus. Postoperatively, intestinal obstruction is clinically a state of inhibition of gastrointestinal motor function that occurs after laparotomy, and a rapid recovery of postoperative gastrointestinal function is a crucial factor in accelerating the time of discharge. In general, the gastrointestinal motility function normally recovers within 2 to 3 days after open surgery, and often progresses to paralytic ileus that does not heal naturally and continues for more than 3 days. Surgery is meant to include laparoscopic or arthroscopy and other robotic surgeries, as well as surgery for uterine and other organs, as well as surgery for small bowel disease.
본 발명에서 사용하는 생약은 종래부터 오랜 기간 사용으로 안전성이 확보되어 독성이나 부작용이 거의 없는 것으로 볼 수 있지만, 전통적인 탕제 제조 방법이 아니라 유기 용매를 이용하여 추출할 경우 추출 용매 및 조성물 조합비에 따라 독성 및 부작용이 발생할 가능성을 배제할 수 없다. 이에 따라, 본 발명에서는 확실한 약효를 보이면서 의약품으로의 개발 가능한 정도로 독성 및 부작용이 경감되는 추출 조건 및 조합비를 찾게 되었다. 본 발명에 따라 산초와 지실 추출물을 포함하는 조성물로서, 추출 용매와 조합비가 한정된 조성물은 독성 및 부작용이 거의 없으므로 위장관 운동 장애 질환의 개선, 치료 및 예방 목적으로 장기간 복용시에도 안심하고 사용할 수 있다.The herbal medicine used in the present invention can be seen that there is almost no toxicity or side effects since it is secured by using it for a long time in the past, but it is toxic according to the extraction solvent and composition combination ratio when extracted using an organic solvent rather than the traditional method of preparing a powder. And the likelihood of side effects occurring. Accordingly, in the present invention, the extraction conditions and the combination ratio are reduced to the extent that toxicity and side effects are reduced to the extent possible to develop the drug while showing a certain drug efficacy. According to the present invention, as a composition comprising an extract of Sancho and fruiting filaments, the composition having a limited combination ratio with the extraction solvent has little toxicity and side effects, and thus can be used safely even for long-term administration for the purpose of improving, treating and preventing gastrointestinal motility disorders.
본 발명의 일 태양에 따른 산초 및 지실 추출물을 특정 조성비로 포함하는 위장관 운동장애 질환의 개선, 치료 또는 예방용 경구제제는 약학적으로 허용 가능한 담체, 부형제 및/또는 희석제를 포함할 수 있으며, 통상의 방법에 따라 산제, 과립제, 정제, 캡슐제, 현탁액, 에멀전, 시럽, 에어졸 등의 제형으로 제제화될 수 있다. 본 발명의 경구제제의 투여 용량은 산초 및 지실 추출물 유효성분을 1일 체중 ㎏ 당 0.1 내지 100 ㎎의 용량으로 1 내지 수 회로 나누어 투여할 수 있다.Oral preparations for ameliorating, treating or preventing gastrointestinal motility disorders comprising the extracts of Sancho and perilla according to one aspect of the present invention may include pharmaceutically acceptable carriers, excipients and / or diluents. It can be formulated in the form of powders, granules, tablets, capsules, suspensions, emulsions, syrups, aerosols and the like according to the method of. The dosage of the oral preparation of the present invention may be administered by dividing the herbicidal and fruiting extract active ingredients into doses of 0.1 to 100 mg / kg body weight per day.
본 발명의 다른 태양에 따른 산초 및 지실 추출물을 특정 조성비로 포함하는 기능성 위장관 운동장애 개선용 식품, 건강보조식품 또는 건강기능식품은 식품학적으로 허용 가능한 담체 및/또는 첨가제를 포함할 수 있으며, 통상의 방법에 따라 식품으로 제제화될 수 있다. 본 발명의 식품은 기능성 위장관 운동장애 개선이 기대되는 범위 내에서 적절하게 생약 조성물의 함량을 가감할 수 있으며, 산초 및 지실 추출물 유효성분을 식품 총 중량에 대하여 0.1 내지 99 중량%, 바람직하게는 1 내지 90 중량% 범위로 포함할 수 있다.Functional gastrointestinal motility disorders foods, health supplements or functional foods comprising the extract of Sancho and fruit juice according to another aspect of the present invention in a specific composition ratio may include a food acceptable carrier and / or additives, usually It may be formulated into a food according to the method of. Foods of the present invention can be appropriately added or reduced the content of the herbal composition within the range expected to improve functional gastrointestinal motility disorders, and 0.1 to 99% by weight, based on the total weight of the food extract of the active ingredient of the herbaceous and fruiting, preferably 1 To 90% by weight.
본 발명에 따른 생약 조성물은 지실 및 산초 추출물의 조합을 포함하여, 지실 또는 산초 추출물을 단독으로 투여하는 경우와 비교할 때 위장관 운동, 특히 수술후 장폐색을 현저하게 개선하여 위장관 운동장애 질환의 개선, 치료 또는 예방에 탁월한 효과를 나타낸다. 또한, 전통적으로 오랜 기간 사용되어 안정성이 확보된 생약으로 구성될 뿐 아니라, 추출 용매와 조합비를 조정하여 약효를 유지하면서 독성 및 부작용을 감소시켰으므로, 장기간 사용에도 부작용이나 독성의 우려가 거의 없다.The herbal composition according to the present invention includes a combination of fruit and pepper extracts, which significantly improves gastrointestinal motility, especially postoperative intestinal obstruction, compared with the case of administering fruit or pepper extract alone to improve, treat or treat gastrointestinal motility disorders. Excellent effect on prevention. In addition, it is traditionally used for a long time and is composed of herbal drugs that ensure the stability, and adjusted the ratio of the extraction solvent and the combination to reduce the toxicity and side effects while maintaining the efficacy, there is little concern of side effects or toxicity even in long-term use.
이하, 본 발명을 실시예 및 실험예를 통해 더욱 구체적으로 설명한다. 단, 하기 실시예는 본 발명의 예시일 뿐, 본 발명의 범위가 이들 만으로 한정되는 것은 아니다.Hereinafter, the present invention will be described in more detail through Examples and Experimental Examples. However, the following Examples are only examples of the present invention, and the scope of the present invention is not limited to these.
제조실시예Manufacturing Example 1: 지실 및 산초 단독 생약 추출물의 제조 1: Preparation of Herbs and Herbs Extract of Herbal Medicine
1-1. 지실 단독 추출물의 제조1-1. Preparation of Fruity Fruit Extract
경동시장(서울)에서 건조된 지실을 구입하여 협잡물을 제거하고 실험에 사용하였다. 건조 지실 100 g에 800 mL의 70%, 80%, 및 90% 에탄올 수용액을 가해 상온에서 24시간 동안 추출하고, 추출액을 55∼65 ℃로 감압 농축한 후 건조시켜 각 용매별 지실 추출물, 즉 70%, 80%, 및 90% 에탄올 가용 지실 추출물들(이하, P70E, P80E 및 P90E 라 지칭함)을 수득하였다. 다음 표 1은 각 추출물의 수율을 나타낸 것이다.The dried fruit room was purchased at Gyeongdong Market (Seoul) to remove impurities and used for experiments. To 100 g of dried cellar, 800 mL of 70%, 80%, and 90% ethanol aqueous solution was added and extracted at room temperature for 24 hours, and the extract was concentrated under reduced pressure to 55-65 ° C. and dried, followed by drying. %, 80%, and 90% ethanol soluble fate extracts (hereinafter referred to as P70E, P80E and P90E) were obtained. Table 1 shows the yield of each extract.
1-2 산초 단독 추출물의 제조1-2 Preparation of single extract
경동시장(서울)에서 건조된 산초를 구입하여 협잡물을 제거하고 실험에 사용하였다. 건조 산초 250 g에 1750 mL의 30%, 50%, 70%, 90% 에탄올 수용액을 가해 상온에서 24시간 동안 추출하고, 추출액을 55∼65 ℃로 감압 농축한 후 건조시켜 각 용매별 산초 추출물, 즉 30%, 50%, 70%, 및 90% 에탄올 가용 산초 추출물들(이하, Z30E, Z50E, Z70E 및 Z90E 라 지칭함)을 수득하였다. 추가로, 건조 산초 250 g에 1750 mL의 증류수를 가해 100 ℃에서 1시간 동안 열탕 추출하고, 추출액을 55∼65 ℃로 감압 농축한 후 건조시켜 얻은 산초 추출물, 즉 열탕 산초 추출물(이하, ZWE 라 지칭함)을 수득하였다. 다음 표 2는 각 추출물의 수율을 나타낸 것이다.Dried pickles from Kyungdong market (Seoul) were purchased and used for experiments. 1750 mL of 30%, 50%, 70%, and 90% ethanol aqueous solution was added to 250 g of dried acid, and the extract was extracted at room temperature for 24 hours. The extract was concentrated under reduced pressure at 55 to 65 ° C. and dried to give an acid extract of each solvent. Ie, 30%, 50%, 70%, and 90% ethanol soluble acidic extracts (hereinafter referred to as Z30E, Z50E, Z70E and Z90E) were obtained. In addition, 1750 mL of distilled water was added to 250 g of dry acid, extracted with boiling water at 100 ° C. for 1 hour, and the extract was concentrated under reduced pressure at 55 to 65 ° C., followed by drying. Refer to). Table 2 shows the yield of each extract.
제조실시예Manufacturing Example 2: 산초 및 지실 추출물의 조합 제조 2: Combination Preparation of Sancho and Fruit Extracts
2-1. 산초 및 지실 추출물 조합 12-1. Sancho and Fructus Extract Combination 1
상기 제조실시예 1-1에서 70% 에탄올로 추출하여 수득한 지실 추출물과 상기 제조실시예 1-2에서 70% 에탄올로 추출하여 수득한 산초 추출물에 대하여, 산초 추출물 중량을 기준으로 지실 추출물을 1:3 및 1:2.3의 중량비로 혼합하여 배합비가 1:3 및 1:2.3인 본 발명의 지실 및 산초 조합 추출물(이하, PZ713 및 PZ7123으로 지칭함)을 제조하여 하기 실험예에서 사용하였다.For the fruit extract obtained by extracting with 70% ethanol in Preparation Example 1-1 and the extract of the extract obtained with 70% ethanol in Preparation Example 1-2, the fruit extract based on the weight of the extract of 1 Mixtures at the weight ratios of: 3 and 1: 2.3 were used to prepare the combined fruit and pepper extract of the present invention (hereinafter referred to as PZ713 and PZ7123) having a mixing ratio of 1: 3 and 1: 2.3, and used in the following experimental examples.
2-2. 산초 및 지실 추출물 조합 22-2. Herb and Fruit Extract Combination 2
상기 제조실시예 1-1에서 70% 에탄올로 추출하여 수득한 지실 추출물과 상기 제조실시예 1-2에서 50% 에탄올로 추출하여 수득한 산초 추출물에 대하여, 산초 추출물 중량을 기준으로 지실 추출물을 1:1, 1:1.5, 1:2.3, 1:3, 1:4, 1:9 및 1:12의 중량비로 혼합하여 배합비가 1:1, 1:1.5, 1:2.3, 1:3, 1:4, 1:9 및 1:12인 본 발명의 지실 및 산초 조합 추출물(이하, PZ511, PZ5115, PZ5123, PZ513, PZ514, PZ519 및 PZ5112라 지칭함)을 제조하여 하기 실험예에서 사용하였다.For the fruit extract obtained by extracting with 70% ethanol in Preparation Example 1-1 and the extract of the extract obtained with 50% ethanol in Preparation Example 1-2, the fruit extract based on the weight of the extract of 1 Mixing ratios of 1: 1, 1: 1.5, 1: 2.3, 1: 3, 1: 4, 1: 9, and 1:12 in a weight ratio of 1: 1, 1: 1.5, 1: 2.3, 1: 3, 1 Fruit and pepper extract extracts of the present invention (hereinafter referred to as PZ511, PZ5115, PZ5123, PZ513, PZ514, PZ519 and PZ5112) of 4: 4, 1: 9 and 1:12 were prepared and used in the following experimental examples.
또한, 상기 제조실시예 1-1에서 70% 에탄올로 추출하여 수득한 지실 단독 추출물과, 상기 제조실시예 1-2에서 50% 에탄올로 추출하여 수득한 산초 단독 추출물을 투여한 군을 하기 실험예 1의 비교군으로서 사용하였다.In addition, the following experimental example was administered to the group administered the only extract obtained by extracting with 70% ethanol in Preparation Example 1-1 and the extract of Sancho alone obtained by extracting with 50% ethanol in Preparation Example 1-2 It was used as a comparative group of 1.
2-3. 산초 및 지실 추출물 조합 32-3. Herb and Fruit Extract Combination 3
상기 제조실시예 1-1에서 70% 에탄올로 추출하여 수득한 지실 추출물과 상기 제조실시예 1-2에서 30% 에탄올로 추출하여 수득한 산초 추출물에 대하여, 산초 추출물 중량을 기준으로 지실 추출물을 1:1, 1:4, 1:9 및 1:12의 중량비로 혼합하여 배합비가 1:1, 1:4, 1:9 및 1:12인 지실 및 산초 조합 추출물(이하, PZ311, PZ314, PZ319 및 PZ3112 라 지칭함)을 수득하여 하기 실험예에서 사용하였다.For the fruit extract obtained by extracting with 70% ethanol in Preparation Example 1-1 and the extract obtained with 30% ethanol in Preparation Example 1-2, the fruit extract based on the weight of the extract of 1 A combination of fruit and acid extracts with mixed ratios of 1: 1, 1: 4, 1: 9 and 1:12 in a weight ratio of 1: 1, 1: 4, 1: 9 and 1:12 (hereinafter, referred to as PZ311, PZ314, and PZ319). And PZ3112) were obtained and used in the following experimental examples.
2-4. 산초 및 지실 추출물 조합 42-4. Herb and Fruit Extract Combination 4
상기 제조실시예 1-1에서 70% 에탄올로 추출하여 수득한 지실 추출물과 상기 제조실시예 1-2에서 열탕 추출하여 수득한 산초 추출물에 대하여, 산초 추출물 중량을 기준으로 지실 추출물을 1:3의 중량비로 혼합하여 배합비가 1:3인 지실 및 산초 조합 추출물(이하, PZW13이라 지칭함)을 수득하여 하기 실험예에서 사용하였다.
For the fruit extract obtained by extracting with 70% ethanol in Preparation Example 1-1 and the extract obtained by boiling water extraction in Preparation Example 1-2, the fruit extract was 1: 3 based on the weight of the extract. Mixing by weight ratio yielded a combined extract of Ji-sil and Sancho (hereinafter referred to as PZW13) having a mixing ratio of 1: 3, which was used in the following experimental example.
실험예Experimental Example 1: One: 수술후After surgery 위장관 기능회복 효과 실험 Gastrointestinal function recovery effect experiment
상기 실시예에서 수득한 생약 조성물들이 수술후 장폐색에 미치는 영향을 알아보기 위하여 하기와 같이 문헌에 개시된 방법에 따라 실험을 수행하였다(Yohei Tokita et al . J Pharmacol Sci. 2007).In order to determine the effect of the herbal compositions obtained in the above examples on postoperative ileus, an experiment was performed according to the method disclosed in the literature as follows (Yohei Tokita et. al . J Pharmacol Sci . 2007).
본 실험예는 수술후 장폐색을 유발시킨 랫드에서 장내 이송율을 측정하는 방법으로, 본 발명에 따른 생약 추출물이 수술후 위장관 기능회복에 미치는 영향을 평가하는 것이다.This experimental example is a method for measuring the intestinal transport rate in the rats induced postoperative ileus, to evaluate the effect of the herbal extract according to the present invention on postoperative gastrointestinal function recovery.
200∼240 g의 수컷 SD 랫드(오리엔트. 대한민국)를 온도 22∼24 ℃, 습도 50~70%로 명암 주기를 유지하면서 1주간 순화 사육하였다. 표준식이 사료와 음수는 자유롭게 섭취하도록 하였다. 시험대상 동물은 24시간 절식시킨 후 정상군을 제외한 나머지 랫드에 수술을 시행하여, 수술후 장폐색(postoperative ileus)을 유도하였다. 수술은 이소플루오란(ASJ9AC. Abbott Lab)으로 호흡마취하고 복부의 약 2 ㎝ 정도를 절개하였다. 소장과 맹장을 조심스럽게 몸 밖으로 꺼내어 맹장으로부터 십이지장까지 약 10분간 손가락으로 마사지하여 자극을 주었다. 마사지를 마친 후 소장과 맹장을 복부의 절개부분을 통해 다시 조심스럽게 넣었다. 그리고 절개 부위는 봉합하였다. 수술후 3시간 30분 경과시, 상기 실시예에서 제조한 지실 및 산초 조합 추출물, 지실 및 산초 각각의 추출물을 시험약물로서 각 5 ㎖/㎏ 용량으로 경구투여하였다. 시험약물은 5% 플루로닉(Fluronic) F-68(P1300, SIGMA)에 현탁하여 사용하였고, 음성대조군에는 시험약물 없이 같은 용량의 5% 플루로닉 F-68을 경구 투여하였다. 정상군은 수술을 시행하지 않은 랫드로서 마취 과정만 동일하게 진행한 후, 시험약물 없이 시험약물 투여군과 같은 용량의 5% Fluronic F-68을 경구투여하였다.200-240 g of male SD rats (Orient, Republic of Korea) were bred for 1 week while maintaining a light / dark cycle at a temperature of 22-24 ° C. and a humidity of 50-70%. Standard diets and negative water were freely consumed. The animals were fasted for 24 hours, and surgery was performed on the rats except the normal group to induce postoperative ileus. Surgery was anesthetized with isofluorane (ASJ9AC. Abbott Lab) and an incision about 2 cm in the abdomen was made. The intestines and appendix were carefully taken out of the body and stimulated by finger massage from the appendix to the duodenum for about 10 minutes. After the massage, the intestines and cecum were carefully inserted again through the incision in the abdomen. The incision site was sutured. At 3 hours and 30 minutes after the operation, the extracts of the combined fruit and pepper extracts prepared in the above examples, the extracts of the fruit and pepper extracts were orally administered at 5 ml / kg doses as test drugs. The test drug was suspended in 5% Pluronic F-68 (P1300, SIGMA), and the negative control group was orally administered the same dose of 5% Pluronic F-68 without the test drug. The normal group underwent the operation of anesthesia as a rat without surgery, and then orally administered 5% Fluronic F-68 at the same dose as the test drug-treated group without the test drug.
투약 30분 경과 후, 상기 정상군, 음성 대조군, 비교군으로서 지실 및 산초 각각의 추출물 단독 투여군, 그리고 본 발명에 따른 지실 및 산초 추출물 조합 투여군 전체에 대하여 생리식염수에 녹인 에반스블루(E2129, SIGMA, 50 ㎎/㎖)를 0.2 mL 경구 투여하였다. 모든 랫드는 에반스블루 투여 20분 경과 후 경추탈골하여 안락사시키고 소장을 적출하였다. 적출된 소장은 전체 길이와 에반스블루의 이동거리를 측정하여 하기 식에 따라 장내이송율(ITR)을 계산한 후 통계처리 하였다. 그 결과를 하기 표 3에 나타낸다.30 minutes after the administration, Evans Blue (E2129, SIGMA, 50 mg / ml) was orally administered 0.2 mL. All rats were euthanized by cervical dislocation 20 minutes after Evansblue administration and small intestine was extracted. The collected small intestine was measured by measuring the total length and the moving distance of Evans blue, and then statistically processed after calculating the intestinal transfer rate (ITR) according to the following equation. The results are shown in Table 3 below.
ITR(%) = 에반스블루 이동거리/전체 소장길이ITR (%) = Evans Blue Travel / Total Collection Length
통계처리는 Prism4(GraphPad)를 사용하여 Unpaired t-test로 유의성을 분석하였으며, 본 발명의 산초 및 지실 추출물 조합 투여군의 약리효과에 대한 유효성은 음성대조군과 비교하여 ( * P < 0.05, ** P < 0.01, *** P < 0.001) 판단하였다.Statistical treatment was analyzed by the Unpaired t-test using Prism4 (GraphPad), the effectiveness of the pharmacological effect of the combination treatment group of Sancho and fruit extract of the present invention compared with the negative control group ( * P <0.05, ** P <0.01, *** P <0.001).
산초추출물(Z30E) 단독 투여군
Acid extract (Z30E) alone administration group
산초추출물(Z50E) 단독 투여군
Acid extract (Z50E) alone administration group
지실
추출물
조합(PZ)
투여군Sancho and
Basement
extract
Combination (PZ)
Administered group
지실추출물(P70E) 단독 투여군
Fruit extract (P70E) alone administration group
상기 표에서 알 수 있듯이, 음성 대조군의 경우 정상군에 비하여 위장관 이송율이 매우 크게 감소하였다. 본 발명에 따른 지실 및 산초 추출물을 조합하여 투여한 결과, 정상군에 근접하거나 상회하는 우수한 위장관 이송율을 나타내었으며, 산초와 지실 각각의 단독 투여군에 대비하여도 현저히 뛰어난 상승효과를 나타내었다.
As can be seen from the table, the negative control group significantly reduced the gastrointestinal transport rate compared to the normal group. As a result of the combination of the extracts of the fruiting and sancho extract according to the present invention, it showed an excellent gastrointestinal transport rate close to or above the normal group, and showed a significantly superior synergistic effect compared to the individual administration group of the sancho and the fruiting.
실험예Experimental Example 2: 2: 랫드에서의In the rat 단회One time 투여 독성실험 Dose Toxicity Test
상기 실시예에서 수득한 생약 조성물들을 랫드에 단회 투여시 독성을 알아보기 위해 아래의 방법에 따라 실험을 수행하였다.In order to determine the toxicity of the herbal composition obtained in the above Example in a single dose to the rat, the experiment was performed according to the following method.
7주령의 수컷 SD 랫드(오리엔트, 대한민국)를 온도 22∼24℃, 습도는 50~70%로 명암 주기를 유지하면서 1주간 순화 사육하였다. 표준식이 사료와 음수는 자유롭게 섭취하도록 하였다. 시험대상 동물은 24시간 절식시킨 후 상기 실시예에서 제조한 산초 및 지실 추출물의 조합을 시험약물로써 각각 10 ㎖/㎏의 투여액량으로 경구 투여하였다. 시험약물은 5% 플루로닉(Pluronic) F-68(P1300, SIGMA)에 현탁하여 사용하였다. 음성대조군에는 시험약물 없이 시험군과 동일한 투여액량의 5% 플루로닉 F-68을 경구 투여하였다.Seven-week-old male SD rats (Orient, South Korea) were bred for 1 week while maintaining a light / dark cycle with a temperature of 22-24 ° C and a humidity of 50-70%. Standard diets and negative water were freely consumed. Animals were fasted for 24 hours, and then the oral herb extracts prepared in Example were administered orally at a dose of 10 ml / kg, respectively. The test drug was used suspended in 5% Pluronic F-68 (P1300, SIGMA). The negative control group was orally administered 5% Pluronic F-68 at the same dose as the test group without the test drug.
시험약물을 단회 경구 투여한 후 사망율 및 부작용을 1주일 동안 관찰하였으며, 다음 표 4는 그 결과를 나타낸 것이다.After a single oral administration of the test drug, mortality and side effects were observed for one week, and Table 4 shows the results.
(㎖/㎏)Volume
(Ml / kg)
산초
및
지실
추출물
조합 (PZ)
투여군
Sancho
And
Basement
extract
Combination (PZ)
Administered group
피모 오염 Caused by secretions around the eyes and nose
Coat hair pollution
피모 오염 Caused by secretions around the eyes and nose
Coat hair pollution
상기 표에서 알 수 있는 바와 같이, 산초 열탕 추출물과 산초 30% 에탄올 추출물의 경우 사망예 및 부작용이 관찰되지 않았으나, 산초 70% 에탄올 추출물과 50% 에탄올 추출물에서는 사망예 및 부작용이 관찰되었다. 즉, 산초 추출시 에탄올 함량이 낮을수록 독성이 경감되는 것을 알 수 있었다.As can be seen from the table, no death and no side effects were observed in the Sancho hot water extract and 30% ethanol extract, but death and side effects were observed in the 70% ethanol extract and 50% ethanol extract. In other words, it was found that the lower the ethanol content of the extract was reduced toxicity.
본 생약 조성물은 안전성이 높은 천연물 생약을 사용한다는 장점과 함께, 안전성 평가를 위해 진행되는 독성시험을 고려하면 적어도 단회 투여 독성시험에서 사망예 및 부작용이 관찰되지 않아야 할 것으로 판단된다. 따라서, 생약 추출물 중 산초 추출물은 독성이 경감된 열탕 또는 30% 이하의 에탄올 수용액으로 추출하여 사용해야 할 것으로 판단된다.
The herbal composition has the advantage of using a high-safety natural product, and considering the ongoing toxicity test for safety evaluation, it is determined that at least a single dose toxicity test should not be observed deaths and side effects. Therefore, the herbal extract of the herbal extracts should be used to extract the toxic hot water or less than 30% ethanol aqueous solution.
실험예Experimental Example 3: 개에서의 경구 투여 독성실험 3: Oral Dose Toxicity in Dogs
상기 실시예에서 수득한 생약 조성물들을 개에게 단회 및 2회 투여시 독성을 알아보기 위해 아래의 방법에 따라 실험을 수행하였다.In order to determine the toxicity of the herbal compositions obtained in the above examples in single and two doses to dogs, experiments were carried out according to the following method.
10∼12 ㎏의 수컷 비글견(오리엔트. 대한민국)을 온도 22∼24 ℃, 습도는 50∼70%로 명암 주기를 유지하면서 한 달 이상 순화 사육하였다. 표준식이 사료와 음수는 자유롭게 섭취하도록 하였다. 시험대상 동물을 24시간 절식시킨 후 상기 실시예에서 제조한 산초 및 지실 추출물의 조합을 시험약물로써 캡슐에 충전하여 경구 투여하였다. 대조군에는 시험약물이 충전되지 않은 캡슐을 경구 투여하였다.Male Beagle dogs (Orient, Republic of Korea) of 10-12 kg were bred for more than a month while maintaining a light / dark cycle at a temperature of 22-24 ° C and a humidity of 50-70%. Standard diets and negative water were freely consumed. After fasting the test animals for 24 hours, the combination of the herbaceous acid and fruit extract prepared in Example was filled into the capsule as a test drug and administered orally. The control group was orally administered a capsule not filled with the test drug.
시험물질을 1∼2회 경구 투여한 후 사망율 및 부작용을 24시간 동안 관찰하였다. 랫드 단회 투여시의 사망예 및 독성 증상을 참조하여 사망예가 나타나지 않을 30% 에탄올 산초 추출물을 포함하는 생약 조성물들과 용량을 선정하여 부작용을 관찰하였다. 다음 표 5는 그 결과를 나타낸 것이다.After oral administration of the test substance once or twice, mortality and adverse events were observed for 24 hours. Adverse events were observed by selecting herbal compositions and doses containing 30% ethanol acid extract that would not show death, referring to mortality and toxicity symptoms in single-dose rats. Table 5 shows the results.
지실 추출물
조합(PZ)
투여군Sancho and
Lychee extract
Combination (PZ)
Administered group
상기 표에서 보듯이, 산초:지실 조성비가 높을수록 독성이 경감되는 것을 관찰할 수 있었다. 즉, 산초의 30% 에탄올 추출물을 포함하는 생약 조성물에서 산초:지실의 조성비가 1:8일 경우 투여용량이 200 ㎎/㎏이면 2회 투여시 구토 및 설사가 관찰되었으나, 산초:지실의 조성비가 1:12일 경우 투여용량 600 ㎎/㎏에서는 구토가 관찰되었으나 200 ㎎/㎏에서는 아무런 부작용도 나타나지 않았다. 따라서, 안전성이 높은 생약을 사용한다는 장점과 안전성 평가시 진행되는 독성시험을 고려할 때, 본 발명의 생약 조성물은 독성이 경감된 열탕 또는 30% 이하의 에탄올 수용액 산초 추출물을 사용하여야 하며, 산초:지실 조성비는 1:8 이상, 바람직하게는 1:8∼1:12 범위 내에서의 제품 개발이 가장 바람직할 것으로 판단된다.As shown in the table, it was observed that the higher the composition of the acidic: fruit chamber, the lower the toxicity. That is, in the herbal composition containing 30% ethanol extract of Sancho, when the composition ratio of Sancho: jiji was 1: 8, if the dose was 200 mg / kg, vomiting and diarrhea were observed when administered twice, but the composition ratio of Sancho: jiji was In case of 1:12, vomiting was observed at the dose of 600 mg / kg, but no adverse effect was observed at 200 mg / kg. Therefore, in consideration of the advantages of using a high-safety herbal medicine and toxicological tests conducted in the safety evaluation, the herbal composition of the present invention should use a hot water or a ethanol solution of 30% or less ethanol solution reduced toxicity, The composition ratio is 1: 8 or more, preferably in the range of 1: 8 to 1:12 product development is judged to be most preferred.
Claims (10)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20120068070 | 2012-06-25 | ||
KR1020120068070 | 2012-06-25 |
Publications (1)
Publication Number | Publication Date |
---|---|
KR20140000627A true KR20140000627A (en) | 2014-01-03 |
Family
ID=50138463
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020130054029A KR20140000627A (en) | 2012-06-25 | 2013-05-13 | Medicinal herb composition for improvement, treatment and prevention of gastrointestinal motility disorders |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR20140000627A (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104042920A (en) * | 2014-06-26 | 2014-09-17 | 青岛市市立医院 | Formula of traditional Chinese medicine for treating ulcerative colitis |
CN105770376A (en) * | 2016-04-27 | 2016-07-20 | 中国中医科学院西苑医院 | Preparation process of traditional Chinese medicine composition for treating gastroesophageal reflux disease |
KR20220047436A (en) * | 2020-10-08 | 2022-04-18 | 주식회사 우제아이엠 | Korean Medicinal Compounds for Improving Gastroesophageal Reflux Disease Comprising Herbal Mixture |
KR20240001538A (en) | 2022-06-27 | 2024-01-03 | 김성겸 | Valuables storage box where valuable are rotated |
-
2013
- 2013-05-13 KR KR1020130054029A patent/KR20140000627A/en not_active Application Discontinuation
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104042920A (en) * | 2014-06-26 | 2014-09-17 | 青岛市市立医院 | Formula of traditional Chinese medicine for treating ulcerative colitis |
CN105770376A (en) * | 2016-04-27 | 2016-07-20 | 中国中医科学院西苑医院 | Preparation process of traditional Chinese medicine composition for treating gastroesophageal reflux disease |
KR20220047436A (en) * | 2020-10-08 | 2022-04-18 | 주식회사 우제아이엠 | Korean Medicinal Compounds for Improving Gastroesophageal Reflux Disease Comprising Herbal Mixture |
KR20240001538A (en) | 2022-06-27 | 2024-01-03 | 김성겸 | Valuables storage box where valuable are rotated |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Kumari et al. | Rauvolfia serpentina L. Benth. ex Kurz.: phytochemical, pharmacological and therapeutic aspects | |
KR101444698B1 (en) | Composition for improvement, treatment and prevention of gastrointestinal motility disorders | |
CN104116734A (en) | Pharmaceutical composition and pharmaceutical preparation for treating oral and throat diseases, and applications and preparation method of the pharmaceutical composition and pharmaceutical preparation | |
KR20140000627A (en) | Medicinal herb composition for improvement, treatment and prevention of gastrointestinal motility disorders | |
CN104815138A (en) | Immature bitter orange extract, preparation and application | |
WO2015192758A1 (en) | Anti-tumor pharmaceutical application of pentacyclic triterpene saponin compounds of szechuan melandium root | |
CN101317904B (en) | Uses of smoked plum extract in resisting virus, bacteria, mycoplasma or chlamydia of livestock and poultry | |
CN103127198B (en) | Combined drug for treating piglet's yellow-white dysentery | |
KR20170023192A (en) | Compositions comprising melatonin and flavonoids for use in the treatment of tumours resistant to chemotherapy | |
KR20150033797A (en) | Pharmaceutical composition for prevention and treatment of atopic skin disease | |
KR100878436B1 (en) | Pharmaceutical composition comprising extract of lonicera japonica for prevention and treatment of digestive ulcer | |
US20240115644A1 (en) | Composition for preventing, improving or treating gastritis or peptic ulcer comprising extract of cinnamomum cassia, fraction of said extract, isolate of said fraction or compounds isolated therefrom | |
KR101556443B1 (en) | A composition for anti-cancer comprising extract of Pinus Koraiensis SIEB | |
CN103417563A (en) | Application of aurantiamarin to preparation of medicine for treating acute and chronic bronchitis | |
KR101710588B1 (en) | A composition comprising the extract of plantago asiatica showing anti-toxoplasma activity | |
CN108567878B (en) | Traditional Chinese medicine composition for preventing and treating fungal dermatopathy | |
JP2008007473A (en) | Cassia obtusifolia l. or cassia tora l. seed extract | |
JPH01172340A (en) | Preventive and remedy for staphylococcal disease of chicken | |
CN103417595B (en) | Traditional Chinese medicine compound and preparing method thereof | |
KR100522176B1 (en) | Composition for improving male sexual function | |
CN105748861A (en) | Traditional Chinese medicine composition for resisting stress reaction, and preparation method and application thereof | |
CN110025782A (en) | A kind of Chinese medicine composition of helicobacter pylori resistant and preparation method thereof | |
RU2549295C1 (en) | Feed additive for poultry | |
CN103393891A (en) | Antiviral compound traditional Chinese medicine for animals, and preparation method and use thereof | |
Poudel et al. | Phytochemical analysis, in vitro antioxidant activity and in vivo anti-inflammatory and analgesic activities of selected medicinal plants of Nepal |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E902 | Notification of reason for refusal | ||
E601 | Decision to refuse application |